218 related articles for article (PubMed ID: 15671296)
1. Preclinical evaluation of a novel episcleral cyclosporine implant for ocular graft-versus-host disease.
Kim H; Csaky KG; Gilger BC; Dunn JP; Lee SS; Tremblay M; de Monasterio F; Tansey G; Yuan P; Bungay PM; Lutz RJ; Robinson MR
Invest Ophthalmol Vis Sci; 2005 Feb; 46(2):655-62. PubMed ID: 15671296
[TBL] [Abstract][Full Text] [Related]
2. A pharmacokinetic and safety evaluation of an episcleral cyclosporine implant for potential use in high-risk keratoplasty rejection.
Lee SS; Kim H; Wang NS; Bungay PM; Gilger BC; Yuan P; Kim J; Csaky KG; Robinson MR
Invest Ophthalmol Vis Sci; 2007 May; 48(5):2023-9. PubMed ID: 17460256
[TBL] [Abstract][Full Text] [Related]
3. A novel bioerodible deep scleral lamellar cyclosporine implant for uveitis.
Gilger BC; Salmon JH; Wilkie DA; Cruysberg LP; Kim J; Hayat M; Kim H; Kim S; Yuan P; Lee SS; Harrington SM; Murray PR; Edelhauser HF; Csaky KG; Robinson MR
Invest Ophthalmol Vis Sci; 2006 Jun; 47(6):2596-605. PubMed ID: 16723476
[TBL] [Abstract][Full Text] [Related]
4. Safety and pharmacokinetics of intravitreal 2-methoxyestradiol implants in normal rabbit and pharmacodynamics in a rat model of choroidal neovascularization.
Robinson MR; Baffi J; Yuan P; Sung C; Byrnes G; Cox TA; Csaky KG
Exp Eye Res; 2002 Feb; 74(2):309-17. PubMed ID: 11950241
[TBL] [Abstract][Full Text] [Related]
5. Controlled drug release from an ocular implant: an evaluation using dynamic three-dimensional magnetic resonance imaging.
Kim H; Robinson MR; Lizak MJ; Tansey G; Lutz RJ; Yuan P; Wang NS; Csaky KG
Invest Ophthalmol Vis Sci; 2004 Aug; 45(8):2722-31. PubMed ID: 15277497
[TBL] [Abstract][Full Text] [Related]
6. Effect of cyclosporine on conjunctival mucin in a canine keratoconjunctivitis sicca model.
Moore CP; McHugh JB; Thorne JG; Phillips TE
Invest Ophthalmol Vis Sci; 2001 Mar; 42(3):653-9. PubMed ID: 11222523
[TBL] [Abstract][Full Text] [Related]
7. Use of episcleral cyclosporine implants in dogs with keratoconjunctivitis sicca: pilot study.
Barachetti L; Rampazzo A; Mortellaro CM; Scevola S; Gilger BC
Vet Ophthalmol; 2015 May; 18(3):234-41. PubMed ID: 24799029
[TBL] [Abstract][Full Text] [Related]
8. Update on ocular graft versus host disease.
Kim SK
Curr Opin Ophthalmol; 2006 Aug; 17(4):344-8. PubMed ID: 16900025
[TBL] [Abstract][Full Text] [Related]
9. Ocular tissue distribution of betamethasone after anterior-episcleral, posterior-episcleral, and anterior-intrascleral placement of nonbiodegradable implants.
Okabe K; Kimura H; Okabe J; Ogura Y
Retina; 2007; 27(6):770-7. PubMed ID: 17621189
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of topical cyclosporine 0.05% in the treatment of dry eye associated with graft versus host disease.
Rao SN; Rao RD
Cornea; 2006 Jul; 25(6):674-8. PubMed ID: 17077659
[TBL] [Abstract][Full Text] [Related]
11. Episcleral cyclosporine A implants for the management of unilateral keratoconjunctivitis sicca in an 8-year-old mare.
Mackenzie CJ; Carslake HB; Robin M; Kent RJ; Malalana F
Vet Ophthalmol; 2017 Jan; 20(1):79-83. PubMed ID: 26945681
[TBL] [Abstract][Full Text] [Related]
12. Clinical evaluation of pimecrolimus eye drops for treatment of canine keratoconjunctivitis sicca: a comparison with cyclosporine A.
Ofri R; Lambrou GN; Allgoewer I; Graenitz U; Pena TM; Spiess BM; Latour E
Vet J; 2009 Jan; 179(1):70-7. PubMed ID: 17950639
[TBL] [Abstract][Full Text] [Related]
13. Feasibility of drug delivery to the posterior pole of the rabbit eye with an episcleral implant.
Kato A; Kimura H; Okabe K; Okabe J; Kunou N; Ogura Y
Invest Ophthalmol Vis Sci; 2004 Jan; 45(1):238-44. PubMed ID: 14691179
[TBL] [Abstract][Full Text] [Related]
14. Delivery from episcleral exoplants.
Pontes de Carvalho RA; Krausse ML; Murphree AL; Schmitt EE; Campochiaro PA; Maumenee IH
Invest Ophthalmol Vis Sci; 2006 Oct; 47(10):4532-9. PubMed ID: 17003449
[TBL] [Abstract][Full Text] [Related]
15. Ocular surface and tear functions after topical cyclosporine treatment in dry eye patients with chronic graft-versus-host disease.
Wang Y; Ogawa Y; Dogru M; Kawai M; Tatematsu Y; Uchino M; Okada N; Igarashi A; Kujira A; Fujishima H; Okamoto S; Shimazaki J; Tsubota K
Bone Marrow Transplant; 2008 Feb; 41(3):293-302. PubMed ID: 17982500
[TBL] [Abstract][Full Text] [Related]
16. [A 0,05% cyclosporine treatment of the advanced dry eye syndrome].
Kujawa A; Rózycki R
Klin Oczna; 2005; 107(4-6):280-6. PubMed ID: 16118939
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo release characteristics of Tacrolimus (FK506) from an episcleral drug-delivery implant.
Mai S; Lin L; Yang W; Deng X; Xie Z; Zong Y; Li Y; Gao Q
J Ocul Pharmacol Ther; 2014 Oct; 30(8):670-80. PubMed ID: 24933028
[TBL] [Abstract][Full Text] [Related]
18. Topical ophthalmic cyclosporine: pharmacology and clinical uses.
Donnenfeld E; Pflugfelder SC
Surv Ophthalmol; 2009; 54(3):321-38. PubMed ID: 19422961
[TBL] [Abstract][Full Text] [Related]
19. Ocular findings after allogeneic hematopoietic stem cell transplantation.
Tabbara KF; Al-Ghamdi A; Al-Mohareb F; Ayas M; Chaudhri N; Al-Sharif F; Al-Zahrani H; Mohammed SY; Nassar A; Aljurf M
Ophthalmology; 2009 Sep; 116(9):1624-9. PubMed ID: 19729097
[TBL] [Abstract][Full Text] [Related]
20. [Intraocular implantation of cyclosporine A drug delivery system in the treatment of experimental uveitis].
Dong XG; Xu YM; Yuan GQ; Shi WY; Xie LX; Wang SG
Zhonghua Yan Ke Za Zhi; 2005 Jul; 41(7):636-41. PubMed ID: 16080900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
